🇺🇸 Magnesium glucoheptonate in United States

22 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 22

Most-reported reactions

1. Carnitine Deficiency — 3 reports (13.64%)
2. Hyperlactacidaemia — 3 reports (13.64%)
3. Anaemia — 2 reports (9.09%)
4. Constipation — 2 reports (9.09%)
5. Dystonia — 2 reports (9.09%)
6. Febrile Neutropenia — 2 reports (9.09%)
7. Gastrointestinal Haemorrhage — 2 reports (9.09%)
8. Hyperaesthesia — 2 reports (9.09%)
9. Muscle Spasms — 2 reports (9.09%)
10. Pain In Extremity — 2 reports (9.09%)

Source database →

Frequently asked questions

Is Magnesium glucoheptonate approved in United States?

Magnesium glucoheptonate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Magnesium glucoheptonate in United States?

Scarborough General Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.